Shares of BioScrip, Inc. (NASDAQ:BIOS) have been assigned a consensus rating of “Hold” from the seven analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $3.94.

A number of research firms have commented on BIOS. Zacks Investment Research lowered BioScrip from a “buy” rating to a “hold” rating in a research report on Monday, August 14th. SunTrust Banks, Inc. raised BioScrip from a “hold” rating to a “buy” rating and upped their price target for the company from $3.25 to $3.75 in a research report on Thursday, August 10th. BidaskClub lowered BioScrip from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. Barrington Research upped their price target on BioScrip to $3.50 and gave the company an “outperform” rating in a research report on Monday, June 26th. Finally, ValuEngine lowered BioScrip from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd.

BioScrip (NASDAQ BIOS) traded down 0.41% during midday trading on Friday, reaching $2.43. The company had a trading volume of 471,380 shares. The stock’s market capitalization is $309.76 million. BioScrip has a one year low of $0.98 and a one year high of $3.39. The company has a 50-day moving average price of $2.69 and a 200-day moving average price of $2.40.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). The business had revenue of $218.11 million during the quarter, compared to analyst estimates of $220.05 million. BioScrip’s revenue was down 6.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.14) earnings per share. On average, equities analysts expect that BioScrip will post ($0.55) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “BioScrip, Inc. (BIOS) Receives $3.94 Average Price Target from Brokerages” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.watchlistnews.com/bioscrip-inc-bios-receives-3-94-average-price-target-from-brokerages/1644499.html.

In other news, Director Coliseum Capital Management, L sold 886,478 shares of the stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $3.08, for a total value of $2,730,352.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael G. Bronfein sold 27,000 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $2.69, for a total value of $72,630.00. Following the completion of the transaction, the director now directly owns 129,669 shares of the company’s stock, valued at approximately $348,809.61. The disclosure for this sale can be found here. Insiders have sold a total of 3,760,419 shares of company stock valued at $11,144,519 in the last ninety days. 0.80% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in BIOS. Gilder Gagnon Howe & Co. LLC raised its position in shares of BioScrip by 248.4% in the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock worth $41,298,000 after acquiring an additional 10,845,410 shares in the last quarter. FMR LLC raised its position in shares of BioScrip by 36.1% in the 1st quarter. FMR LLC now owns 4,803,000 shares of the company’s stock worth $8,165,000 after acquiring an additional 1,273,205 shares in the last quarter. Alta Fundamental Advisers LLC raised its position in shares of BioScrip by 36.9% in the 2nd quarter. Alta Fundamental Advisers LLC now owns 3,035,164 shares of the company’s stock worth $8,240,000 after acquiring an additional 818,000 shares in the last quarter. California Public Employees Retirement System raised its position in shares of BioScrip by 37.5% in the 1st quarter. California Public Employees Retirement System now owns 663,700 shares of the company’s stock worth $1,128,000 after acquiring an additional 181,000 shares in the last quarter. Finally, Roanoke Asset Management Corp NY raised its position in shares of BioScrip by 72.9% in the 2nd quarter. Roanoke Asset Management Corp NY now owns 403,280 shares of the company’s stock worth $1,095,000 after acquiring an additional 170,000 shares in the last quarter. 84.77% of the stock is owned by hedge funds and other institutional investors.

BioScrip Company Profile

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.